There are various registries for patients with peritoneal metastases (PM) that aid pooling of data and generate evidence that dictates current clinical practice. This manuscript describes the setting up of the Indian HIPEC registry that was set up with a similar goal by a group of Indian surgeons. This is a registry for patients with PM treated with CRS and HIPEC in India. It also acts as a database for storing treatment-related information. Patients with PM from colorectal ovarian, gastric, appendiceal tumors, and other rare peritoneal tumors/metastases from rare tumors are enrolled in the registry. A coordinator updates the disease status of patients on a yearly basis. A private organization maintains the database. A non-disclosure agreement is signed between the company and each surgeon contributing to the registry to maintain confidentiality. For enrolling patients, securing institutional permission depends on the requirement of each institute; patient consent is mandatory. Data entry can be prospective or retrospective. To propose and conduct a study, the approval of a scientific committee linked to the registry is required. The Indian HIPEC registry is a practical database for Indian surgeons. There is no regulatory body that mandates collection and publication of scientific data in India. The onus is on each surgeon to capture valuable information pertaining to these common and rare diseases that could contribute to the existing scientific knowledge and guide the treatment of these patients in the future. The next challenge will be to enter data into the registry.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705519 | PMC |
http://dx.doi.org/10.1007/s13193-017-0693-7 | DOI Listing |
Gynecol Oncol Rep
February 2025
Dept of Surgical Oncology, Aster International Institute of Oncology, Bangalore, India.
Background: The role of enhanced recovery after surgery (ERAS) in cytoreductive surgery and/or Hyperthermic Intraperitoneal Chemotherapy HIPEC) is evolving, with promising results that improve patient outcomes. This consensus exercise was carried out to address and standardize components of the ERAS protocol pertinent to the Indian context.
Method: The modified Delphi method was employed with two rounds of voting.
Ann Surg Oncol
December 2024
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
JCO Glob Oncol
December 2024
Department of Surgical Oncology, Shalby Cancer and Research Institute, Ahmedabad, India.
Indian J Cancer
January 2024
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Ann Surg Oncol
February 2025
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: No guidelines exist regarding the management of the uninvolved uterus or adnexa (fallopian tubes and/or ovaries) in patients with peritoneal metastases (PM) from non-gynecologic malignancies. It is unclear whether salpingo-oophorectomy, hysterectomy, or both should be performed when a complete pelvic peritonectomy is otherwise warranted.
Methods: A 25-item electronic survey was sent to 225 surgeons worldwide who routinely perform cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!